NR2F6 was also defined as an intracellular immune checkpoint in tumor-infiltrating T cells and is significantly related to the survival outcomes of numerous cancers, such as head and neck squamous cell carcinoma, early-stage cervical cancer, and colon cancer [38–40]. Here, NR2F6 is linked to cervical carcinoma.